Interpreting CROWN's Key Efficacy Outcomes: PFS Milestones, Survival Probabilities, and the Overall Survival Story

This segment takes a deep dive into the efficacy data from the 7-year CROWN study update, presenting some of the most striking numbers in recent oncology and unpacking what they mean for patients and clinicians in practice. Dr. Lovly opens by reviewing the headline findings: a median progression-free survival with lorlatinib that remains not reached at 7 years, compared to just 9.1 months with crizotinib — a hazard ratio of 0.19 that underscores the magnitude of benefit. Intracranial disease control follows a similarly dramatic pattern, with median time to intracranial progression also not reached for lorlatinib versus 16.4 months for crizotinib, reflecting the drug's deliberate design to penetrate the CNS effectively.

A central focus of the discussion is the clinically meaningful milestone finding that patients on lorlatinib who remain progression-free at 2 years carry an approximately 79% probability of still being progression-free at year 7. Drs. Lovly and Shaw explore what this means in practice — noting that the highest risk of progression occurs within the first 2 years, with roughly 20% of patients relapsing in year one and another 10% in year two. For patients who clear that initial window, the data offer something rare in advanced lung cancer: genuine reassurance. Dr. Shaw describes this as a transformative conversation to have with patients, offering a moment to “exhale” from the anxiety of anticipated resistance and relapse. She also previews emerging biomarker analyses — including findings around tumor mutation burden and TP53 mutations — that may one day help identify early progressors before treatment begins. The segment closes with a discussion of the still-maturing overall survival data, contextualizing why the PFS benefit already seen with lorlatinib — exceeding the median overall survival reported with second-generation inhibitors like alectinib at 6.75 years — points strongly toward survival outcomes that may be truly unprecedented.